These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 30486896)

  • 41. STAT1-mediated inhibition of FOXM1 enhances gemcitabine sensitivity in pancreatic cancer.
    Liu C; Shi J; Li Q; Li Z; Lou C; Zhao Q; Zhu Y; Zhan F; Lian J; Wang B; Guan X; Fang L; Li Z; Wang Y; Zhou B; Yao Y; Zhang Y
    Clin Sci (Lond); 2019 Mar; 133(5):645-663. PubMed ID: 30782607
    [TBL] [Abstract][Full Text] [Related]  

  • 42. LncRNA HIF1A-AS1 Promotes Gemcitabine Resistance of Pancreatic Cancer by Enhancing Glycolysis through Modulating the AKT/YB1/HIF1α Pathway.
    Xu F; Huang M; Chen Q; Niu Y; Hu Y; Hu P; Chen D; He C; Huang K; Zeng Z; Tang J; Wang F; Zhao Y; Wang C; Zhao G
    Cancer Res; 2021 Nov; 81(22):5678-5691. PubMed ID: 34593522
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inhibition of Notch3 enhances sensitivity to gemcitabine in pancreatic cancer through an inactivation of PI3K/Akt-dependent pathway.
    Yao J; Qian C
    Med Oncol; 2010 Sep; 27(3):1017-22. PubMed ID: 19816816
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Src Inhibition Can Synergize with Gemcitabine and Reverse Resistance in Triple Negative Breast Cancer Cells via the AKT/c-Jun Pathway.
    Wu ZH; Lin C; Liu MM; Zhang J; Tao ZH; Hu XC
    PLoS One; 2016; 11(12):e0169230. PubMed ID: 28036386
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells.
    Hong SP; Wen J; Bang S; Park S; Song SY
    Int J Cancer; 2009 Nov; 125(10):2323-31. PubMed ID: 19598259
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer.
    Kawaguchi H; Terai Y; Tanabe A; Sasaki H; Takai M; Fujiwara S; Ashihara K; Tanaka Y; Tanaka T; Tsunetoh S; Kanemura M; Ohmichi M
    J Ovarian Res; 2014 Apr; 7():38. PubMed ID: 24713296
    [TBL] [Abstract][Full Text] [Related]  

  • 47. miRNA-93-5p Promotes Gemcitabine Resistance in Pancreatic Cancer Cells by Targeting the PTEN-Mediated PI3K/Akt Signaling Pathway.
    Wu Y; Xu W; Yang Y; Zhang Z
    Ann Clin Lab Sci; 2021 May; 51(3):310-320. PubMed ID: 34162560
    [TBL] [Abstract][Full Text] [Related]  

  • 48. WNT5A modulates cell cycle progression and contributes to the chemoresistance in pancreatic cancer cells.
    Wei W; Sun HH; Li N; Li HY; Li X; Li Q; Shen XH
    Hepatobiliary Pancreat Dis Int; 2014 Oct; 13(5):529-38. PubMed ID: 25308364
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine.
    Yokoi K; Fidler IJ
    Clin Cancer Res; 2004 Apr; 10(7):2299-306. PubMed ID: 15073105
    [TBL] [Abstract][Full Text] [Related]  

  • 50. BRM/SMARCA2 promotes the proliferation and chemoresistance of pancreatic cancer cells by targeting JAK2/STAT3 signaling.
    Zhang Z; Wang F; Du C; Guo H; Ma L; Liu X; Kornmann M; Tian X; Yang Y
    Cancer Lett; 2017 Aug; 402():213-224. PubMed ID: 28602977
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antitumor activity and combined inhibitory effect of ceritinib with gemcitabine in pancreatic cancer.
    Jamshed MB; Munir F; Shahid N; Sadiq U; Muhammad SA; Ghanem NB; Zhong H; Li X; Zhang Q
    Am J Physiol Gastrointest Liver Physiol; 2020 Jan; 318(1):G109-G119. PubMed ID: 31736340
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combination Effects of Hispidin and Gemcitabine
    Chandimali N; Huynh DL; Jin WY; Kwon T
    Anticancer Res; 2018 Jul; 38(7):3967-3975. PubMed ID: 29970519
    [TBL] [Abstract][Full Text] [Related]  

  • 53. DKK3 blocked translocation of β-catenin/EMT induced by hypoxia and improved gemcitabine therapeutic effect in pancreatic cancer Bxpc-3 cell.
    Guo Q; Qin W
    J Cell Mol Med; 2015 Dec; 19(12):2832-41. PubMed ID: 26395974
    [TBL] [Abstract][Full Text] [Related]  

  • 54.
    Tadros S; Shukla SK; King RJ; Gunda V; Vernucci E; Abrego J; Chaika NV; Yu F; Lazenby AJ; Berim L; Grem J; Sasson AR; Singh PK
    Cancer Res; 2017 Oct; 77(20):5503-5517. PubMed ID: 28811332
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hypoxia Promotes Pancreatic Cancer Cell Dedifferentiation to Stem-Like Cell Phenotypes With High Tumorigenic Potential by the HIF-1α/Notch Signaling Pathway.
    Mu R; Zou YK; Tu K; Wang DB; Tang D; Yu Z; Zhao L
    Pancreas; 2021 May-Jun 01; 50(5):756-765. PubMed ID: 34016895
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Enhancement of the antiproliferative activity of gemcitabine by modulation of c-Met pathway in pancreatic cancer.
    Avan A; Quint K; Nicolini F; Funel N; Frampton AE; Maftouh M; Pelliccioni S; Schuurhuis GJ; Peters GJ; Giovannetti E
    Curr Pharm Des; 2013; 19(5):940-50. PubMed ID: 22973962
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Epigallocatechin-3-Gallate (EGCG) Suppresses Pancreatic Cancer Cell Growth, Invasion, and Migration partly through the Inhibition of Akt Pathway and Epithelial-Mesenchymal Transition: Enhanced Efficacy when Combined with Gemcitabine.
    Wei R; Penso NEC; Hackman RM; Wang Y; Mackenzie GG
    Nutrients; 2019 Aug; 11(8):. PubMed ID: 31405071
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-κB signaling.
    Liu J; Ma J; Wu Z; Li W; Zhang D; Han L; Wang F; Reindl KM; Wu E; Ma Q
    BMC Cancer; 2014 Sep; 14():686. PubMed ID: 25240403
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Insulin-like growth factor 1 receptor promotes the growth and chemoresistance of pancreatic cancer.
    Tian X; Hao K; Qin C; Xie K; Xie X; Yang Y
    Dig Dis Sci; 2013 Sep; 58(9):2705-12. PubMed ID: 23589145
    [TBL] [Abstract][Full Text] [Related]  

  • 60. HMGA1 is a molecular determinant of chemoresistance to gemcitabine in pancreatic adenocarcinoma.
    Liau SS; Whang E
    Clin Cancer Res; 2008 Mar; 14(5):1470-7. PubMed ID: 18316571
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.